These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 30476795)
21. Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex. Steffens M; Szabo B; Klar M; Rominger A; Zentner J; Feuerstein TJ Neuroscience; 2003; 120(2):455-65. PubMed ID: 12890515 [TBL] [Abstract][Full Text] [Related]
22. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Niederhoffer N; Szabo B Br J Pharmacol; 1999 Jan; 126(2):457-66. PubMed ID: 10077239 [TBL] [Abstract][Full Text] [Related]
23. Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Moranta D; Esteban S; García-Sevilla JA Naunyn Schmiedebergs Arch Pharmacol; 2004 May; 369(5):516-24. PubMed ID: 15064921 [TBL] [Abstract][Full Text] [Related]
25. Genetic deletion of dopamine D1 receptors increases the sensitivity to cannabinoid CB1 receptor antagonist-precipitated withdrawal when compared with wild-type littermates: studies in female mice repeatedly exposed to the Spice cannabinoid HU-210. Serrano A; Vadas E; Ferrer B; Bilbao A; Granado N; Suárez J; Pavon FJ; Moratalla R; Rodríguez de Fonseca F Psychopharmacology (Berl); 2021 Feb; 238(2):551-557. PubMed ID: 33410990 [TBL] [Abstract][Full Text] [Related]
26. A real time screening assay for cannabinoid CB1 receptor-mediated signaling. Andersen HK; Piroli GG; Walsh KB J Pharmacol Toxicol Methods; 2018; 94(Pt 1):44-49. PubMed ID: 29730318 [TBL] [Abstract][Full Text] [Related]
27. Cannabinoid exposure in pubertal rats increases spontaneous ethanol consumption and NMDA receptor associated protein levels. Klugmann M; Klippenstein V; Leweke FM; Spanagel R; Schneider M Int J Neuropsychopharmacol; 2011 May; 14(4):505-17. PubMed ID: 21211107 [TBL] [Abstract][Full Text] [Related]
28. Acute, chronic and withdrawal effects of the cannabinoid receptor agonist WIN55212-2 on the sequential activation of MAPK/Raf-MEK-ERK signaling in the rat cerebral frontal cortex: short-term regulation by intrinsic and extrinsic pathways. Moranta D; Esteban S; García-Sevilla JA J Neurosci Res; 2007 Feb; 85(3):656-67. PubMed ID: 17139682 [TBL] [Abstract][Full Text] [Related]
29. Opposite function of dopamine D1 and N-methyl-D-aspartate receptors in striatal cannabinoid-mediated signaling. Daigle TL; Wetsel WC; Caron MG Eur J Neurosci; 2011 Nov; 34(9):1378-89. PubMed ID: 22034973 [TBL] [Abstract][Full Text] [Related]
30. Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation. Selley DE; Rorrer WK; Breivogel CS; Zimmer AM; Zimmer A; Martin BR; Sim-Selley LJ J Neurochem; 2001 May; 77(4):1048-57. PubMed ID: 11359870 [TBL] [Abstract][Full Text] [Related]
31. Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Verrico CD; Jentsch JD; Roth RH Synapse; 2003 Jul; 49(1):61-6. PubMed ID: 12710016 [TBL] [Abstract][Full Text] [Related]
32. Chronic Exposure to WIN55,212-2 During Adolescence Alters Prefrontal Dopamine Turnover and Induces Sensorimotor Deficits in Adult Rats. Abboussi O; Andaloussi ZL; Chris AD; Taghzouti K Neurotox Res; 2020 Oct; 38(3):682-690. PubMed ID: 32757167 [TBL] [Abstract][Full Text] [Related]
33. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Martín AB; Fernandez-Espejo E; Ferrer B; Gorriti MA; Bilbao A; Navarro M; Rodriguez de Fonseca F; Moratalla R Neuropsychopharmacology; 2008 Jun; 33(7):1667-79. PubMed ID: 17957223 [TBL] [Abstract][Full Text] [Related]
34. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations. Mulè F; Amato A; Baldassano S; Serio R Pharmacol Res; 2007 Sep; 56(3):185-92. PubMed ID: 17656103 [TBL] [Abstract][Full Text] [Related]
35. Long lasting effects of chronic WIN55,212-2 treatment on mesostriatal dopaminergic and cannabinoid systems in the rat brain. Perdikaris P; Tsarouchi M; Fanarioti E; Natsaridis E; Mitsacos A; Giompres P Neuropharmacology; 2018 Feb; 129():1-15. PubMed ID: 29113897 [TBL] [Abstract][Full Text] [Related]
36. Investigation of non-CB Breivogel CS; McPartland JM; Parekh B J Recept Signal Transduct Res; 2018 Aug; 38(4):316-326. PubMed ID: 30376752 [TBL] [Abstract][Full Text] [Related]
37. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Fernández-López D; Martínez-Orgado J; Nuñez E; Romero J; Lorenzo P; Moro MA; Lizasoain I Pediatr Res; 2006 Aug; 60(2):169-73. PubMed ID: 16864698 [TBL] [Abstract][Full Text] [Related]
38. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Diana M; Melis M; Gessa GL Eur J Neurosci; 1998 Sep; 10(9):2825-30. PubMed ID: 9758152 [TBL] [Abstract][Full Text] [Related]
39. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Fattore L; Cossu G; Martellotta CM; Fratta W Psychopharmacology (Berl); 2001 Aug; 156(4):410-6. PubMed ID: 11498718 [TBL] [Abstract][Full Text] [Related]